Axogen, Inc.
About Axogen, Inc.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $225.2M
- Net income
- -$15.7M
- Total assets
- $221.7M
- Market cap
- $2.3B
- Gross margin
- 74.3%
- Operating margin
- -3.5%
- Net margin
- -7.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $225.2M
- Cost of revenue
- $57.9M
- Gross profit
- $167.4M
- Operating expenses
- $175.2M
- Operating income
- -$7.8M
- Income tax
- $0
- Net income
- -$15.7M
- EPS (basic)
- $-0.34
- EPS (diluted)
- $-0.34
Balance sheet
- Total assets
- $221.7M
- Current assets
- $120.4M
- Total liabilities
- $92.8M
- Current liabilities
- $23.6M
- Shareholders’ equity
- $128.8M
Cash flow
- Operating cash flow
- $812.0K
- Investing cash flow
- -$5.3M
- Financing cash flow
- $10.5M
- Net cash flow
- $6.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.3B
- EPS (diluted)
- $-0.34
- Shares outstanding
- 54.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 17, 1986
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $15.7M in FY2025.
- Revenue grew 77% from FY2021 to FY2025.
- Gross margin of 74.3%, net margin -7.0%.
- Trading 5% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Axogen, Inc..
Write a review
News about Axogen, Inc.
News & sentiment via Polygon.io
